Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
136.53%
Net Margin
135.80%
Efficiency Metrics
Revenue per Expense Ratio
-6,360,710.0
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
136.53%
Income Tax Rate
0.00%
EPS
-0.1000000000
Balance Sheet Analysis
Current Ratio
0.14
Cash Ratio
1.65
Working Capital
$-10.62M
Debt to Equity
0.01
Debt to Assets
0.68%
Equity Ratio
98.09%
Cash Flow Analysis
Operating Cash Flow Ratio
-668.41%
Free Cash Flow Ratio
-668.41%
CapEx to Revenue
0.00%
Dividends Paid
$53.56M
Stock Buybacks
$30.52M
Total Shareholder Returns
$84.08M
Cash Position Change
-71.46%
Key Takeaways (2023 FY)
Revenue declined by 104.53653220341%, indicating potential market challenges
Increased dividend payments by 14.53%
Detailed Growth Metrics
Core Performance
Revenue
-104.54%
Net Income
-103.11%
EPS
-103.15%
Operating Income
-221.64%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
20.97%
Operating Cash Flow
-22.90%
Free Cash Flow
-22.90%
Balance Sheet Health
Assets
-8.42%
Debt
5,128.47%
Book Value per Share
-5.95%
Inventory
0.00%
Shareholder Returns
Dividends per Share
14.53%
Shares Outstanding
-3.61%
Long Term Trends
3Y Revenue/Share
28.64%
5Y Revenue/Share
95.24%
3Y Dividend/Share
17.98%
5Y Dividend/Share
1.19%